Merrion Announces Positive Clinical Results For Osteoporosis Drug MER 103
Wed, 17 Jan 2007 08:00 AM EST
... Merrion Pharmaceuticals Ltd, an international specialty pharmaceutical company, today announced the successful completion of a clinical pharmacology study of MER 103, a novel oral formulation of alendronate sodium. MER 103 is an enteric- coated tablet of alendronate and GIPET(TM), Merrion's proprietary platform technology which increases drug absorption. [click link for full article] ...
Related Topics
- Clinical Trials
- Osteoporosis
- Pharmacology
- Psychopharmacology
- Drug Safety
- Prescription Drugs
- Urinalysis
- Tarceva
- Drug Side Effects
- Drug Abuse
- Drug Information
- Tb
- Clinical Growth Charts
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Raloxifene
- Depression
- Pamidronate Injection
- Hyperthyroidism
- Teriparatide Injection

Not Signed In -


